Meta-analysis of the placebo-treated groups in clinical trials of progressive MS

Neurology

Volumn 46, Issue 6, 1996, Pages 1613-1619

  Weinshenker, Brian G ^a   Issa, Maher ^b   Baskerville, Jon ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MEPREDNISONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG EFFECT; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE SCLEROSIS; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL MODEL; TREATMENT FAILURE;

EID: 0029902571     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.6.1613     Document Type: Article

References (16)

1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
2. Weinshenker BG, Sibley WA. Natural history and treatment of multiple sclerosis. Curr Opin Neurol Neurosurg 1992;5: 203-211.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
4. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991;114:1057-1067.
5. Ellison GW, Myers LW, Leake BD, et al. Design strategies in multiple sclerosis clinical trials. Ann Neurol 1994;36:S108-S112.
6. Ellison GW, Myers LW, Mickey MR, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989;39:1018-1026.
7. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;2:179-183.
8. The Multiple Sclerosis Study Group: efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990;27:591-605.
9. The Canadian Cooperative Multiple Sclerosis Study Group: the Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441-446.
10. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-1056.
11. Weinshenker BG, Issa M, Baskerville J. Long- and short-term outcome of multiple sclerosis: A three year follow-up study. Arch Neurol 1996;53:353-358.
12. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995;13:119-146.
13. Weiner HL, Mackin GA, Orau EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the northeast cooperative multiple sclerosis treatment group. Neurology 1993;43:910-918.
14. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991;41:20-25.
15. Baskerville J, Weinshenker BG. Viable predictive enrollment schemes for clinical trials. Submitted, 1995.
16. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.